Engineered immune cells take on deadly brain cancer in early trial
NCT ID NCT05353530
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 24 times
Summary
This early-phase study tests whether a new type of immune cell therapy, made from the patient's own cells and modified to target a protein called CD70, is safe and feasible for adults with glioblastoma and children with high-grade gliomas. The therapy includes an extra modification to help the cells travel to the tumor. The study involves 39 participants and focuses on safety and the ability to produce and infuse the cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Florida Health
Gainesville, Florida, 32608, United States
Conditions
Explore the condition pages connected to this study.